uniQure secures $175 million debt facility from Hercules Capital

uniQure N.V. (NASDAQ: QURE) entered into a $175 million senior secured term loan facility with Hercules Capital Inc. (NYSE: HTGC), the gene therapy company announced.

The facility refinances uniQure's existing $50 million debt and extends the maturity from January 2027 to October 2030. An additional $100 million becomes available subject to achieving regulatory and financial milestones related to AMT-130, the company's investigational gene therapy for Huntington's disease. A third tranche of up to $25 million requires Hercules' approval.

The loan carries a floating interest rate of the greater of 9.45% or prime rate plus 2.45%, reflecting a current rate of 9.70%. This compares to the previous floating rate of 11.95%.

"This non-dilutive financing keeps funds from the outstanding $50 million debt available until 2030 and provides access to an additional $125 million," said Christian Klemt, chief financial officer of uniQure. The company anticipates a potential commercial launch of AMT-130 in the United States in 2026.

Leerink Partners served as exclusive financial advisor to uniQure on the transaction.

The Lexington, Massachusetts-based company develops gene therapies for patients with severe medical conditions. Hercules Capital provides senior secured venture growth loans to venture capital-backed companies in technology and life sciences industries.

You May Also Be Interested In